Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods

  • Ginex, Tiziana
  • Garaigorta, Urtzi
  • Ramírez, David
  • Castro, Victoria
  • Nozal, Vanesa
  • Maestro, Inés
  • Garcia-Carceles, Javier
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Gastaminza, Pablo
  • Gil, Carmen
The unprecedent situation generated by the COVID-19 global emergency has prompted scientists around the world to actively work to fight against this pandemic. In this sense, it is remarkable the number of drug repurposing efforts trying to shed light into the COVID-19 patients treatment. In the attempt to proceed toward a proper rationalization of the search for new antivirals among approved drugs, we carried out a hierarchical in silico/in vitro protocol which successfully combines virtual and biological screening to speed up the identification of host-directed therapies against COVID-19 in an effective way. A successful combination of a multi-target virtual screening approach focused on host-based targets related to viral entry and experimental evaluation of the antiviral activity of selected compounds has been carried out. As a result, three different potentially repurposable drugs interfering with viral entry, cepharantine, imatinib and efloxate, have been identified., Funding from CSIC (201980E024, 202020E103 and PIE-RD-COVID-19 ref. E202020E079), EVA (European Virus Archive; grant agreement No 871029), FONDECYT grant Nº 11180604 and CONICYT-PCI grant Nº REDES190074 is acknowledged. Dr. R. Molenkamp (Erasmus University Medical Center, Rotterdam, Netherlands; participant of the EVA-GLOBAL project) is acknowledged for the SARS32 CoV-2 strain NL/2020 virus. Dr. F. L. (Inserm-Lyon) is acknowledged for the materials required to produce retroviral pseudotypes, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Label-free plasmonic biosensor for rapid, quantitative, and highly sensitive COVID-19 serology: implementation and clinical validation

  • Calvo-Lozano, Olalla
  • Sierra, Miquel
  • Soler, María
  • Estévez, M. Carmen
  • Chiscano- Camón, Luis
  • Ruiz-Sanmartín, Adolfo
  • Ruiz-Rodriguez, Juan Carlos
  • Ferrer, Ricard
  • González-López, Juan José
  • Esperalba, Juliana
  • Fernández-Nava, Candela
  • Bueno, Leticia
  • López-Aladid, Rubén
  • Torres, Antoni
  • Fernández-Barat, Laia
  • Attoumani, Sarah
  • Charrel, Remi
  • Coutard, Bruno
  • Lechuga, Laura M.
Serological tests are essential for the control and management of COVID-19 pandemic, not only for current and historical diagnostics but especially for surveillance, epidemiological, and acquired immunity studies. Clinical COVID-19 serology is routinely performed by enzymatic or chemiluminescence immunoassays (i.e., ELISA or CLIA), which provide good sensitivities at the expense of relatively long turnaround times and specialized laboratory settings. Rapid serological tests, based on lateral flow assays, have also been developed and widely commercialized, but they suffer from limited reliability due to relatively low sensitivity and specificity. We have developed and validated a direct serological biosensor assay employing proprietary technology based on Surface Plasmon Resonance (SPR). The biosensor offers a rapid -less than 15 min- identification and quantification of SARS-CoV-2 antibodies directly in clinical samples, without the need of any signal amplification. The portable plasmonic biosensor device employs a custom-designed multi-antigen sensor biochip, combining the two main viral antigens (RBD peptide and N protein), for simultaneous detection of human antibodies targeting both antigens. The SPR serology assay reaches detection limits in the low ng mL-1 range employing polyclonal antibodies as standard, which are well below the commonly detected antibody levels in COVID-19 patients. The assay has also been implemented employing the first WHO approved anti-SARS-CoV-2 immunoglobulin standard. We have carried out a clinical validation with COVID-19 positive and negative samples (n=120) that demonstrates the excellent diagnostic sensitivity (99%) and specificity (100%). This positions our biosensor device as an accurate, robust, and easy-to-use diagnostics tool for rapid and reliable COVID-19 serology to be employed both at laboratory and decentralized settings for the management of COVID-19 patients and for the evaluation of immunological status during vaccination, treatment or in front of emerging variants., H2020 Research and Innovation Programme of the European Commission Project, No. 101003544 Spanish Research Agency (AEI, grant no. SEV-2017-0706AEI, grant no. SEV-2017-0706) Spanish Ministry of Science and Innovation and the Spanish Research Agency and the European Social Fund (ESF)BES-2017-080527 GENCAT-DGRIS COVID EU H2020 Programme (644956) Plan Nacional de I+D+i 2013-2016 ISCIII- Ministerio de Ciencia e Innovación, Vall d’Hebron University Hospital Biobank PT17/0015/0047 European Virus Archive GLOBAL (EVA-GLOBAL) EU Horizon 2020 (grant agreement No. 871029) Fundació Glòria Soler for COVIDBANK collection Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

SARS-CoV-2 fears green: the chlorophyll catabolite Pheophorbide a is a potent antiviral

  • Jiménez-Alemán, G. H.
  • Castro, Victoria
  • Longdaitsbehere, Addis
  • Gutiérrez-Rodríguez, Marta
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Solano, Roberto
The SARS-CoV-2 pandemic is having devastating consequences worldwide. Although vaccination advances at good pace, effectiveness against emerging variants of the virus is unpredictable. The virus has displayed a remarkable resistance to treatments and no drugs have been proved fully effective against Covid-19. Thus, despite the international efforts, there is still an urgent need for new potent and safe antivirals against SARS-CoV-2. Here we exploited the enormous potential of plant metabolism, in particular the bryophyte Marchantia polymorpha, and following a bioactivity-guided fractionation and mass-spectrometry approach, identified a potent SARS-CoV-2 antiviral. We found that the chlorophyll derivative Pheophorbide a (PheoA), a natural porphyrin similar to animal Protoporphyrin IX, has an extraordinary antiviral activity against SARS-CoV-2 preventing infection of cultured monkey and human cells, without noticeable citotoxicity. We also show that PheoA prevents coronavirus entry into the cells by directly targeting the viral particle. Besides SARS-CoV-2, PheoA also displayed a broad-spectrum antiviral activity against (+)strand RNA viral pathogens such as HCV, West Nile, and other coronaviruses, but not against (-)strand RNA viruses, such as VSV. Our results indicate that PheoA displays a remarkable potency and a satisfactory therapeutic index, and suggest that it may be considered as a potential candidate for antiviral therapy against SARS-CoV-2. Moreover, PheoA adds to remdesivir's efficiency and is currently employed in photoactivable cancer therapies in humans., This research was funded by CSIC (PIE-RD-COVID-19 ref 202040E236 to R.S., PIE-RD COVID-19 ref. E202020E079 to P.G and U.G, and CSIC-CoV19-153 ref PIE-202080E221 to M.G-R.). Funding from EVA (European Virus Archive; grant agreement No 871029) is gratefully acknowledge. GH. J-A. was supported by the Deutsche Forschungsgemeinschaft (Individual Research Grant JI 241/2-1)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Identification of small molecules with virus growth enhancement properties

  • García-Murria, Maria Jesús
  • Gadea-Salom, Laura
  • Moreno, Sandra
  • Zaragoza, Óscar
  • Brun Torres, Alejandro
  • Mingarro, Ismael
  • Martínez-Gil, Luis
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused the pandemic disease known as coronavirus disease 2019 (COVID-19). COVID-19 vaccines were developed at record speed and were authorized approximately a year after the original outbreak. This fast response saved the lives of countless individuals and reduced the disease burden of many more. The experience has served as a reminder of the necessity to implement solid vaccine development platforms and fast production pipelines. Manufacturing vaccines for enveloped viruses, including some SARS-CoV-2 vaccines, often relies on the production of large quantities of viruses in vitro. Thus, speeding up or increasing virus production would expedite vaccine development. With this objective in mind, we established a high throughput screening (HTS) to identify small molecules that enhance or speed up host-virus membrane fusion. Among the HTS hits, we identified that ethynylestradiol augments SARS-CoV-2 fusion activity in both the absence and presence of TMPRSS2. Furthermore, we confirmed that ethynylestradiol can boost the growth of not only SARS-CoV-2 but also Influenza A virus in vitro. A small molecule with these characteristics could be implemented to improve vaccines production., We thank the Generalitat Valenciana (PROMETEO/2019/065) and the Spanish Ministry of Science and Innovation (PID2020-119111GB-I00). We thank P. Selvi for excellent technical assistance. O.Z. is funded by grant PID2020-114546RB-I00 from National Research Agency (Spanish Ministry for Science and Innovation). This publication was also supported by the European Virus Archive GLOBAL (EVA-GLOBAL) project which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement 871029., No